Relationships Between the Apolipoprotein Levels and Sarcopenia in Inpatients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

DOI: https://doi.org/10.2147/dmso.s461324

2024-05-21

Diabetes Metabolic Syndrome and Obesity Targets and Therapy

Abstract:Yang Sun, 1, 2 Bo-Wei Liu, 2 Xin Zhang, 2 Fu-Zai Yin 2 1 Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China; 2 Department of Endocrinology, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, People's Republic of China Correspondence: Fu-Zai Yin, Email Background: Apolipoprotein (Apo) may be associated with sarcopenia in elderly inpatients with type 2 diabetes mellitus (T2DM), but fewer studies are available. In this study, we explored the association of ApoA1, ApoB, and ApoB/ApoA1 with sarcopenia and compared the predictive role of Apo indicators for sarcopenia in an elderly T2DM. Objective: To investigate the relationships between the Apo and sarcopenia in elderly inpatients with T2DM. Methods: This study included 253 inpatients with T2DM (mean age of 70.11± 5.44 years, 32.8% male). The inpatients were divided into the sarcopenic group (n = 100) and non-sarcopenic group (n = 153). The associations among the Apo and sarcopenia were assessed using multivariate analyses. Results: Inpatients in the sarcopenia group showed lower ApoA1 levels than those in the non-sarcopenia group (1.25± 0.21 vs 1.36± 0.20 g/L, P < 0.05) and showed higher ApoB/ApoA1 and ApoB levels than those in the non-sarcopenia group (0.82± 0.27 vs 0.69± 0.19 g/L, P < 0.05;1.00± 0.32 vs 0.93± 0.24 g/L, P < 0.05, respectively). After adjusting for age and BMI, the logistic regression model indicated that ApoA1 was a protective factor for elderly inpatients with T2DM sarcopenia.(OR =0.079,95% CI: 0.021~0.306, P < 0.05);ApoB and AopB/AopA1 were risk factors for elderly inpatients with T2DM sarcopenia.(OR =3.578,95% CI:1.318~9.715, P < 0.05;OR =16.440,95% CI:4.437~60.427, P < 0.05, respectively). AopB/AopA1 provided an AUC value of 0.765 in elderly men.(95% CI: 0.665~0.866, P< 0.05). Conclusion: ApoA1, AopB, and AopB/AopA1 are associated with sarcopenia in elderly inpatients with T2DM, and AopB/AopA1 may be a potential predictor of sarcopenia in elderly men with T2DM. Keywords: type 2 diabetes mellitus, sarcopenia, Apolipoprotein A1, Apolipoprotein B, Apolipoprotein B/A1 Sarcopenia is defined as the age-related loss of skeletal muscle mass and function. 1 With increasing global aging, sarcopenia is rapidly increasing among people over 65 years of age. 2 Sarcopenia can pose a serious threat to the physical health of older adults and can lead to old age, disability, hospitalization and even death. 3–5 The etiology of sarcopenia is complex and involves various factors such as muscle wasting, changes in endocrine function, chronic illnesses, inflammation, insulin resistance, and inadequate nutrition. 6 Several studies have indicated a potential correlation between dyslipidemia and sarcopenia. 7,8 Dysregulation of lipid metabolism is intricately linked to muscle physiology and metabolism, ultimately resulting in muscle pathology and dysfunction. 9 Dyslipidemia may exacerbate sarcopenia by promoting fat accumulation within muscle fibers, impairing mitochondrial function, and inducing oxidative stress, abnormal insulin signaling, and an inflammatory cascade. 10 It has been reported that the decline in proximal leg strength among individuals with T2DM may be linked to diabetic peripheral neuropathy, while the decrease in distal leg strength is attributed to the accumulation of intramuscular fat. 11 Furthermore, a study conducted on elderly inpatients in China revealed that elevated levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) could serve as potential risk factors for sarcopenia in this population. 12 Park found a negative correlation between grip strength and levels of TC, TG, and LDL-C in middle-aged and older adults, while high-density lipoprotein cholesterol (HDL-C) showed a positive correlation. 13 Apo play a crucial role in regulating lipid metabolism by stabilizing lipoprotein structure, facilitating lipid transport, enhancing immunogenicity of lipoproteins, and modulating levels of different lipoproteins. 14 ApoA1 and ApoB are two of the most clinically significant Apo. ApoA1, the main structural protein of HDL-C, plays a crucial role in cholesterol efflux and cellular cholesterol homeostasis. 15 ApoB is the predominant protein constituent of LDL-C and serves as a marker for LDL-C levels. 16 In recent years, there has been a growing focus on the role of Apo in cardiovascular disease, specifically the AopB/AopA1 has demonstrated notable advantage in predicting the risk of atherosclerotic cardiovascular disease. 15,17,18 It is apparent t -Abstract Truncated-

endocrinology & metabolism